Vireo Growth (VREOF) Other financing activities (2021 - 2025)
Vireo Growth (VREOF) reported Other financing activities of $15406.0 for Q2 2025, down 33.34% sequentially from $23110.0 in Q1 2025.
Vireo Growth (VREOF) Other financing activities (2021 - 2025) Analysis & Trends
Vireo Growth (VREOF) has 3 years of Other financing activities data on file, last reported at $15406.0 in Q2 2025.
- For the quarter ending Q2 2025, Other financing activities changed N/A year-over-year to $15406.0; the trailing twelve-month figure through Dec 2025 stood at $38516.0 (down 65.04% YoY), and the FY2025 full-year result was $38516.0, down 44.71% from the prior year.
- Other financing activities retreated to $15406.0 in Q2 2025, from $23110.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $966156.0 in Q1 2021 to a low of $15406.0 in Q2 2025.
- A 3-year average of $185897.7 and a median of $57009.0 in 2021 frame the typical range for Other financing activities.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 15,406.00 |
| Jun 30, 2025 | 15,406.00 |
| Mar 31, 2025 | 23,110.00 |
| Mar 31, 2025 | 23,110.00 |
| Dec 31, 2024 | 53,163.00 |
| Dec 31, 2024 | 53,163.00 |
| Dec 31, 2021 | 57,009.00 |
| Dec 31, 2021 | 57,009.00 |
| Sep 30, 2021 | 76,873.00 |
| Sep 30, 2021 | 76,873.00 |
| Jun 30, 2021 | 109,567.00 |
| Jun 30, 2021 | 109,567.00 |
| Mar 31, 2021 | 966,156.00 |
| Mar 31, 2021 | 966,156.00 |